System for delivering drug with enhanced bioacceptability

• US 4,723,957 A
• Filed: 02/07/1986
• Issued: 02/09/1988
• Est. Priority Date: 02/07/1986
• Status: Expired due to Term

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Theeuwes, Felix, Wong, Patrick S. L., Guittard, George V., Magruder, Paul R.
• Primary Examiner(s): Yasko, John D.
• Assistant Examiner(s): Kartchner, Gene B.
• Application Number:
  US06/827,027
• Time in Patent Office: 732 Days
• Field of Search: 604/890-897, 427/3, 526/93, 525/426, 424/78, 424/80
• US Class Current: 424/679
• CPC Class Codes: A61K 9/0004 Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
• CPC Class Codes: A61M 31/002 Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50

Abstract

A composition of matter comprising a drug, a neutral hydrogel and an ionic hydrogel. The composition can be administered from a delivery system to a biological receptor over time.

Claims

1. A process for lessening the incidence of irritation of a mucosal environment associated with the beneficial drug potassium chloride that produces irritation of a mucosal environment, said process comprising the steps of administering a composition comprising polyethylene oxide, potassium carboxyvinyl polymer and potassium chloride to a mucosal environment, lessening the incidence of unwanted irritation by the polyethylene oxide and potassium carboxyvinyl polymer cooperating in the presence of fluid in the mucosal environment reduce direct contact of the potassium chloride within the mucosal tissue, thereby lessening the incidence of irritation associated with potassium chloride therapy.

2. A process for lessening the incidence of irritation of a mucosal environment associated with a drug that produces irritation of a mucosal environment, said process comprising administering a composition comprising means for lessening the incidence of irritation associated with a drug that produces irritation on contact, said means comprising (a) a first hydrogel that is essentially neutral in fluid in the mucosal environment which first hydrogel interacts with the fluid and swells, and (b) a second hydrogel that is ionic in fluid in the mucosal environment which second hydrogel interacts with the fluid and swells to a lesser volume than the first hydrogel, and which process lessens the incidence of irritation by the first hydrogel and second hydrogel acting together in the mucosal environment to lessen the incidence of irritation of the mucosal tissue associated with the drug.